PT  - JOURNAL ARTICLE
AU  - Tanaka, H
AU  - Makino, Y
AU  - Dahlman-Wright, K
AU  - Gustafsson, J A
AU  - Okamoto, K
AU  - Makino, I
AU  - Wright KD [corrected to Dahlman-Wright, K ]
TI  - Zinc ions antagonize the inhibitory effect of aurothiomalate on glucocorticoid receptor function at physiological concentrations.
DP  - 1995 Nov 01
TA  - Molecular Pharmacology
PG  - 938--945
VI  - 48
IP  - 5
4099  - http://molpharm.aspetjournals.org/content/48/5/938.short
4100  - http://molpharm.aspetjournals.org/content/48/5/938.full
SO  - Mol Pharmacol1995 Nov 01; 48
AB  - The water-soluble gold preparation aurothiomalate, which contains gold as Au(I), is frequently prescribed for patients with rheumatoid arthritis as a disease-modifying agent. We report that aurothiomalate negatively modulates glucocorticoid hormone action; it represses the ligand- and DNA-binding activities and the transactivation function of the glucocorticoid receptor. We suggested the existence of endogenous titrating activities of Au(I) because otherwise administration of aurothiomalate to a patient with rheumatoid arthritis would be expected to result in peripheral insensitivity to glucocorticoids and worsen the patient's status. Focusing on metal ions that are present in vivo, we found that Zn(II) counteracts the inhibitory effect of Au(I) on glucocorticoid receptor function. This complementary effect of Zn(II) was observed at physiological concentrations. We suggest that Zn(II) preserves glucocorticoid receptor function in target tissues and maintains hormone responsiveness, even with chrysotherapy.